View in EDS

A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.

Saved in:
Bibliographic Details
Title: A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.
Authors: Jung M; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Park SH; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Kim H; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Kim Y; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Yun UJ; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Hwang J; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Kim HS; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Lee CK; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea., Kim H; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea., Lee C; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea., Koo DH; Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea., Jeung HC; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea., Zang DY; Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea., Song EK; Division of Oncology-Hematology, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea., Rha SY; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.; Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Source: Cancer research and treatment [Cancer Res Treat] 2026 May 04. Date of Electronic Publication: 2026 May 04.
Publication Type: Journal Article
Journal Info: Publisher: Korean Cancer Association Country of Publication: Korea (South) NLM ID: 101155137 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2005-9256 (Electronic) Linking ISSN: 15982998 NLM ISO Abbreviation: Cancer Res Treat Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42086076
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Jung+M%22">Jung M</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Park+SH%22">Park SH</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Kim+H%22">Kim H</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Kim+Y%22">Kim Y</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Yun+UJ%22">Yun UJ</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Hwang+J%22">Hwang J</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Kim+HS%22">Kim HS</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Lee+CK%22">Lee CK</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Kim+H%22">Kim H</searchLink>; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Lee+C%22">Lee C</searchLink>; Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Koo+DH%22">Koo DH</searchLink>; Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Jeung+HC%22">Jeung HC</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.<br /><searchLink fieldCode="AU" term="%22Zang+DY%22">Zang DY</searchLink>; Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea.<br /><searchLink fieldCode="AU" term="%22Song+EK%22">Song EK</searchLink>; Division of Oncology-Hematology, Department of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea.<br /><searchLink fieldCode="AU" term="%22Rha+SY%22">Rha SY</searchLink>; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.; Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, Korea.; Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101155137%22">Cancer research and treatment</searchLink> [Cancer Res Treat] 2026 May 04. <i>Date of Electronic Publication: </i>2026 May 04.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Korean+Cancer+Association%22">Korean Cancer Association </searchLink><i>Country of Publication: </i>Korea (South) <i>NLM ID: </i>101155137 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2005-9256 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215982998%22">15982998 </searchLink><i>NLM ISO Abbreviation: </i>Cancer Res Treat <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42086076
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.4143/crt.2025.1352
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: A Phase Ib/II Study of Pemigatinib in Combination with Paclitaxel in Patients with Gastric Cancer with FGFs/FGFRs Alterations.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Jung M
      – PersonEntity:
          Name:
            NameFull: Park SH
      – PersonEntity:
          Name:
            NameFull: Kim H
      – PersonEntity:
          Name:
            NameFull: Kim Y
      – PersonEntity:
          Name:
            NameFull: Yun UJ
      – PersonEntity:
          Name:
            NameFull: Hwang J
      – PersonEntity:
          Name:
            NameFull: Kim HS
      – PersonEntity:
          Name:
            NameFull: Lee CK
      – PersonEntity:
          Name:
            NameFull: Kim H
      – PersonEntity:
          Name:
            NameFull: Lee C
      – PersonEntity:
          Name:
            NameFull: Koo DH
      – PersonEntity:
          Name:
            NameFull: Jeung HC
      – PersonEntity:
          Name:
            NameFull: Zang DY
      – PersonEntity:
          Name:
            NameFull: Song EK
      – PersonEntity:
          Name:
            NameFull: Rha SY
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 04
              M: 05
              Text: 2026 May 04
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2005-9256
          Titles:
            – TitleFull: Cancer research and treatment
              Type: main
ResultId 1